The new ACAM2000™ vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks

Expert Review of Vaccines

Volumn 8, Issue 7, 2009, Pages 841-850

  Handley, Lauren ^a   Buller, Robert Mark ^a   Frey, Sharon E ^a   Bellone, Clifford ^a   Parker, Scott ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACAM2000; Dryvax ; Immunogenicity; Modified vaccinia Ankara; Smallpox; Vaccine

Indexed keywords

ANTIVIRUS AGENT; CMX 001; DNA VACCINE; SMALLPOX VACCINE; ST 246; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ATOPIC DERMATITIS; BACTERIUM CONTAMINATION; BIOLOGICAL WARFARE; CLINICAL TRIAL; DRUG CONTAMINATION; DRUG CONTRAINDICATION; DRUG MANUFACTURE; ECZEMA; ECZEMA VACCINATUM; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MONKEYPOX; MYOCARDITIS; MYOPERICARDITIS; NONHUMAN; ORTHOPOXVIRUS; PERICARDITIS; POXVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SEIZURE; SMALLPOX; SMALLPOX VIRUS; SPONTANEOUS ABORTION; VACCINATION; VACCINIA; VIRUS STRAIN; EPIDEMIC; IMMUNOLOGY; METHODOLOGY;

BIOTERRORISM; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; HUMANS; SMALLPOX; SMALLPOX VACCINE;

EID: 67650465924     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.55     Document Type: Review

References (93)

1. Branda JA, Ruoff K. Bioterrorism. Clinical recognition and primary management. Am. J. Clin. Pathol. 117(Suppl.), S116-S123 (2002).
2. Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2, 17-34 (2007). • Comprehensive review of monkeypoxvirus infections in humans and animals. (Pubitemid 46766996)
3. Henderson DA, Borio LL, Lane JM. Smallpox and vaccinia. In: Vaccines. Plotkin SA, Orenstein WA (Eds). Elsevier Inc., PA, USA, 123-153 (2004).
4. Package insert. Acambis, Inc. ACAM2000 Smallpox (Vaccinia) Vaccine, Live (2008). • Package insert for ACAM2000™ describing dosage instructions, contraindications and adverse reactions, among others.
5. Murphy FA, Osburn BI. Adventitious agents and smallpox vaccine in strategic national stockpile. Emerg. Infect. Dis. 11(7), 1086-1089 (2005). (Pubitemid 40880910)
6. Osborne JD, Da Silva M, Frace AM et al. Genomic differences of vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine 25(52), 8807-8832 (2007). (Pubitemid 350199592)
7. Kutinova L, Ludvikova V, Simonova V et al. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine 13(5), 487-493 (1995).
8. Weltzin R, Liu J, Pugachev KV et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9(9), 1125-1130 (2003). • Definitive paper describing the development of ACAM1000, including preclinical and clinical data. (Pubitemid 37173695)
9. Marennikova SS, Chimishkyan KL, Maltseva NN, Shelukhina EM, Fedorov VV. Proceedings of: The Symposium on Smallpox. Yugoslavia Academy of Sciences and Arts. Zagreb, Yugoslavia, 2-3 September 1969.
10. Marennikova SS. International Symposium on Smallpox Vaccine. Bilthoven, The Netherlands, 11-13 October 1972. Karger, Basel (1973).
11. Acambis, Inc. Investigator's brochure for ACAM2000 smallpox vaccine. Cambridge, MA, USA (2002).
12. Monath TP, Caldwell JR, Mundt W et al. ACAM2000 clonal vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2), S31-S44 (2004). • Describes the development of ACAM2000, including preclinical and clinical data comparing ACAM2000 with both ACAM1000™ and Dryvax® . (Pubitemid 39445966)
13. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Investig. Drugs 17(4), 555-564 (2008). • Review of the development of ACAM2000 from conception to licensure by the US FDA. (Pubitemid 351578172)
14. Acambis, Inc. ACAM2000 prescribing information (2009).
15. Acambis, Inc. ACAM2000 smallpox vaccine: Vaccines and Related Biological Products Advisory Committee (VRBPAC). FDA, CBER (2007). • Review of the development of ACAM2000 provided by the FDA Advisory Committee. Includes a summary of immunogenicity and safety data from clinical trials.
16. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26(4), 581-588 (2008).
17. Frey SE, Newman FK, Kennedy JS et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27(10), 1637-1644 (2009). • Presents clear data comparing the three different vaccines.
18. Downie AW, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J. Hyg. (Lond.) 56(4), 479-487 (1958).
19. Downie AW, Saint VL, Goldstein L, Rao AR, Kempe CH. Antibody response in non-haemorrhagic smallpox patients. J. Hyg. (Lond.) 67(4), 609-618 (1969).
20. Mack TM, Noble J Jr, Thomas DB. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21(2), 214-218 (1972).
21. Sarkar JK, Mitra AC, Mukherjee MK. The minimum protective level of antibodies in smallpox. Bull. World Health Organ. 52(3), 307-311 (1975).
22. Artenstein AW, Johnson C, Marbury TC et al. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23(25), 3301-3309 (2005). • Describes immunogenicity and safety data from a Phase II clinical trial comparing undiluted Dryvax to undiluted and diluted ACAM2000 in vaccinia-naive adults.
23. Couch RB, Winokur P, Edwards KM et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J. Infect. Dis. 195(6), 826-832 (2007). (Pubitemid 46363927)
24. Rosenthal S, Merchlinsky M, Chowdhury M. VRBPAC background document: ACAM2000 (live vaccinia virus smallpox vaccine). Vaccines and Related Biological Products Advisory Committee Meeting, 17 May 2007 (2008).
25. Galasso GJ, Mattheis MJ, Cherry JD et al. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Summary. J. Infect. Dis. 135(1), 183-186 (1977).
26. Polak MF, Beunders BJ, Van Der Werff AR, Sanders EW, Van Klaveren J, Brans LM. A comparative study of clinical reaction observed after application of several smallpox vaccines in primary vaccination of young adults. Bull. World Health Organ. 29, 311-322 (1963).
27. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N. Engl. J. Med. 281(22), 1201-1208 (1969). • Describes the historic complications of Dryvax.
28. Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am. J. Epidemiol. 93(4), 238-240 (1971).
29. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122(4), 303-309 (1970).
30. Frey SE, Newman FK, Kennedy JS et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 25(51), 8562-8573 (2007).
31. Parrino J, McCurdy LH, Larkin BD et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25(8), 1513-1525 (2007). (Pubitemid 46074296)
32. Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 289(24), 3278-3282 (2003). (Pubitemid 37430081)
33. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23(17-18), 2078-2081 (2005). (Pubitemid 40341430)
34. Arness MK, Eckart RE, Love SS et al. Myopericarditis following smallpox vaccination. Am. J. Epidemiol. 160(7), 642-651 (2004).
35. Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD. Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am. J. Cardiol. 95(10), 1252-1255 (2005).
36. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24(47-48), 7009-7022 (2006).
37. Hirayama M. Smallpox vaccination in Japan. In: International Medical Foundation of Japan. Fukumi H (Ed.). Saunders, Tokyo, Japan, 113-124 (1975).
38. Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 25(6), 976-984 (2007). • Outlines potential strategies to prevent bioterror smallpox attacks/outbreaks. (Pubitemid 44937441)
39. Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl Acad. Sci. USA 102(11), 4152-4157 (2005). (Pubitemid 40388571)
40. Saito T, Fujii T, Kanatani Y et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 301(10), 1025-1033 (2009).
41. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341(1), 91-101 (2005). (Pubitemid 41356718)
42. Empig C, Higgins K, Edghill-Smith Y, Silvera P. Attenuated smallpox vaccine LC16m8 protects cynomolgus monkeys from Lethal IV monkeypox-zaire challenge, Presented at: ASM-Biodefense Meeting. Washington, DC, USA, 17 February 2006. •• Key report revealing the efficacy of the LC16m8 vaccine in nonhuman primates infected with monkeypoxvirus.
43. Saijo M, Ami Y, Suzaki Y et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol. 80(11), 5179-5188 (2006). (Pubitemid 43752763)
44. Kenner JK, Gurwith M, Luck A et al. Safety and immunogenicity of attenuated smallpox vaccine, LC16m8: results from a Phase 2 study [poster 206E]. In: Proceedings of the 4th Annual American Society for Microbiology Biodefense Research Meeting. Washington, DC, USA, 17 February 2006.
45. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89(22), 10847-10851 (1992).
46. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72(Pt 5), 1031-1038 (1991).
47. Vollmar J, Arndtz N, Eckl KM et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24(12), 2065-2070 (2006). (Pubitemid 43255148)
48. Earl PL, Americo JL, Wyatt LS et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl Acad. Sci. USA 105(31), 10889-10894 (2008).
49. Meseda CA, Garcia AD, Kumar A et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339(2), 164-175 (2005). (Pubitemid 41169785)
50. Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26(14), 1794 - 1804 (2008).
51. Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J. Gen. Virol. 87(Pt 10), 2917-2921 (2006). •• Postexposure treatment with modified vaccinia virus Ankara fails to protect mice against intranasal valaciclovir challenge. (Pubitemid 44463900)
52. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl Acad. Sci. USA 101(13), 4590-4595 (2004). (Pubitemid 38437455)
53. Samuelsson C, Hausmann J, Lauterbach H et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118(5), 1776-1784 (2008). (Pubitemid 351632380)
54. Paran N, Yasemin S, Lustig S et al. Post-exposure immunization with vaccinia virus MVA or conventional Lister vaccine provides solid protection in murine model for human smallpox. J. Infect. Dis. 199(1), 39-48 (2009). • Postexposure vaccination with modified vaccinia virus Ankara or Lister protects mice against an ectromelia virus challenge.
55. Pharmaceutical Technology. Third generation smallpox vaccine (2008).
56. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78(19), 10230-10237 (2004).
57. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254(1), 71-80 (1999). (Pubitemid 29391715)
58. Lai CF, Gong SC, Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J. Virol. 65(10), 5631-5635 (1991).
59. Demkowicz WE, Maa JS, Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J. Virol. 66(1), 386-398 (1992).
60. Davies DH, McCausland MM, Valdez C et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79(18), 11724-11733 (2005). (Pubitemid 41279291)
61. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325(2), 425-431 (2004). (Pubitemid 38902805)
62. Lawrence SJ, Lottenbach KR, Newman FK et al. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis. 196(2), 220-229 (2007). (Pubitemid 47047461)
63. Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine 24(21), 4461-4470 (2006). (Pubitemid 44218846)
64. Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22(25-26), 3358-3366 (2004). (Pubitemid 39078753)
65. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306(1), 181-195 (2003). (Pubitemid 36293408)
66. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25(10), 1814-1823 (2007).
67. Hooper JW, Thompson E, Wilhelmsen C et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78(9), 4433-4443 (2004). (Pubitemid 38501063)
68. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. WHO, Geneva, Switzerland (1988). • Classic text describing variola virus in its historical context.
69. Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect. Dis. 5(10), 647-652 (2005).
70. Government urged to stockpile smallpox vaccine. The Daily Yomiuri, 12 June (2005).
71. News Medical Net. Canada plans to acquire MVA-based smallpox vaccine (2008).
72. Cosma A, Nagaraj R, Staib et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res. Hum. Retroviruses 23(6), 782-793 (2007). (Pubitemid 47047917)
73. Quenelle DC, Buller RM, Parker S et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 51(2), 689-695 (2007). (Pubitemid 46185291)
74. Parker S, Schriewer J, Oberle C et al. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir. Ther. 13(7), 863-873 (2008). •• Demonstration that a single dose of CMX001 given several days postexposure can protect mice against lethal ectromelia challenges.
75. Mortimer PP. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis. 36(5), 622-629 (2003). (Pubitemid 36259569)
76. Parker S, Oberle C, Hembrador E et al. Mousepox in the C57BL/6 strain provides a new model for evaluating anti-poxvirus therapies in mammals. Virology 385(1), 11-21 (2008).
77. Parker S, Handley L, Buller R. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology 3(6), 595-612 (2008). • Comprehensive review of past, present and future therapies to treat orthopoxvirus diseases.
78. Chen N, Li G, Liszewski MK et al. Virulence differences between monkeypoxvirus isolates from West Africa and the Congo basin. Virology 340(1), 46-63 (2005). • Demonstrates that virulence of monkeypoxvirus is generally region specific. (Pubitemid 41191177)
79. CDC. Notice to Readers: newly licensed smallpox vaccine to replace old smallpox vaccine (2008) www.cdc.gov/mmwr/preview/mmwrhtml/ mm5708a6.htm
80. Baxter Vaccines (2007) www.baxtervaccines.com/?node-id=3563.
81. CDC www.cdc.gov/hiv/topics/basic/index.htm
82. National Cancer Institute seer.cancer.gov/csr/1975-2006/ browse-csr.php?section=2&page= sect-02-table.04.html.
83. Safety and immunogenicity study of LC16m8, a modified smallpox vaccine, in healthy, previously unvaccinated volunteers. ID: NCT00103584 (2009) www.ClinicalTrials.gov
84. DoD. DoD Smallpox Vaccination Programe - safety summary. 20 June 2006 www.smallpox.army.mil/event/ SPSafetySum.asp
85. CDC. Household transmission of vaccinia virus from contact with military smallpox vaccinee - Illinois and Indiana, 2007 56(19), 478-481 (2007) www.cdc.gov/mmwr/preview/mmwrhtml/ mm5619a4.htm
86. Acambis, Inc. ACAM2000 clinical trials update, 13 April 2004 www.acambis.co.uk/print.asp?id=782
87. Kim J. VaxGen and Kaketsuken announce agreement to make potentially safer smallpox vaccine for U.S. Japan and US, VaxGen (2002) http://goliath.ecnext. com/coms2/ gi-0199-4166227/vaxgen-and-kaketsukenannounce- agreement.html
88. News Medical Net. Canada plans to acquire MVA-based smallpox vaccine (2008) www.news-medical.net/ news/2007/04/11/23383.aspx
89. Pharmaceutical-technology.com. Bavarian Nordic Smallpox Vaccine Facility, Kvistgård, North Zealand, Denmark (2005) www.pharmaceutical-technology. com/ projects/bavarian-nordic/
90. Safety and immunogenicity of IMVAMUNE® (MVA-BN® ) smallpox vaccine in HIV infected patient. ID: NCT00316589 (2009) http://clinicaltrials. gov/ct2/show/ NCT00316589
91. Safety, tolerability and immune response of IMVAMUNE (MVA-BN) smallpox vaccine in patients with atopic disorders. ID: NCT00189917 (2009) http://clinicaltrials.gov/ct2/show/ NCT00189917
92. A Phase II study on immunogenicity and safety of MVA-BN® (IMVAMUNE™) smallpox vaccine in subjects with atopic dermatitis. ID: NCT00316602 (2009) http://clinicaltrials.gov/ct2/show/ NCT00316602
93. Safety, reactogenicity and immunogenicity of MVA in HSCT subjects. ID: NCT00565929 (2009) http://clinicaltrials.gov/ct2/show/ NCT00565929